Trial Profile
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Brimonidine/brinzolamide (Primary) ; Travoprost/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Alcon
- 08 Aug 2018 Status changed from active, no longer recruiting to discontinued.
- 01 Aug 2018 Trial has been completed in Belgium.
- 07 Jun 2018 Status changed from recruiting to active, no longer recruiting.